references
FINANCIAL REPORT
STATEMENT OF OPERATIONS
FOR THE YEAR ENDED 31 DECEMBER 2015 (with 2014 comparative figures)
(Expressed in EUR)
Notes
2015
2014
INCOME
Public institutional funding: Govern. & public int. organiz. unrestricted Govern. & public int. organiz. restricted Total public institutional funding Private resources: Private foundations, corp. and individuals, unrestricted Private foundations, corp. and individuals, restricted Royalties on drug sales Total private resources Resources from founders: Médecins Sans Frontières, unrestricted Médecins Sans Frontières, restricted Total resources from Founding Partners Other income: Sundry income & reimbursements Other income net TOTAL INCOME 7 8 4,320,562 8,723,041 4,380,683 1,872,551 3,025,486 2,240,641 1,196,696 6,948,617 32,708,277 9 10 2,754,649 2,265,997 37,728,923 10 10 2,035,629 3,238,280 5,273,909 43,002,832 280,513 21,862 1.i (182,369) (160,507) 120,006 6.a-6.b 61,183 (181,189) 3,109,458 7,137,019 4,398,588 2,803,540 1,821,335 1,078,126 1,271,557 6,026,487 27,646,111 2,574,948 1,653,489 31,874,548 1,579,783 2,942,777 4,522,560 36,397,108 158,365 10,290 (103,065) (92,776) 65,589 45,299 (110,888) 73,328 73,328 43,283,345 74,352 74,352 36,555,473 4,000,000 14,944 4,014,944,0 4,000,000 19,102 4,019,102 6 286,879 13,572,650 304 13,859,833 215,633 8,383,666 5,762 8,605,061 13,589,613 11,745,627 25,335,240 13,460,530 10,396,427 23,856,957
SOCIAL MISSION EXPENDITURE
Research & development expenditure: Research & development coordination and supervision Human African trypanosomiasis projects Leishmaniasis projects Chagas disease projects Filarial diseases projects Paediatric HIV projects Other diseases projects (malaria, HCV, mycetoma, and anti-infective) Lead optimization & Portfolio building Total research & development expenditure Strengthening capacities Advocacy expenses TOTAL SOCIAL MISSION EXPENDITURE
NON-SOCIAL MISSION EXPENDITURE
Fundraising General and administration Total non-social mission expenditure TOTAL EXPENDITURE Operating surplus
OTHER INCOME (EXPENSES)
Financial income, net Exchange gain (loss), net TOTAL OTHER INCOME (EXPENSES) Net surplus for the year prior to allocations Release from restricted operating funds Allocation to unrestricted operating funds NET SURPLUS FOR THE YEAR AFTER ALLOCATIONS
70 › DNDi Annual Report 2015
